Joint analysis of D-dimer, N-terminal pro b-type natriuretic peptide, and cardiac troponin I on predicting acute pulmonary embolism relapse and mortality.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
21 07 2021
Historique:
received: 31 01 2021
accepted: 30 06 2021
entrez: 22 7 2021
pubmed: 23 7 2021
medline: 18 11 2021
Statut: epublish

Résumé

Previous studies on the adverse events of acute pulmonary embolism (APE) were mostly limited to single marker, and short follow-up duration, from hospitalization to up to 30 days. We aimed to predict the long-term prognosis of patients with APE by joint assessment of D-dimer, N-Terminal Pro-Brain Natriuretic Peptide (NT-ProBNP), and troponin I (cTnI). Newly diagnosed patients of APE from January 2011 to December 2015 were recruited from three hospitals. Medical information of the patients was collected retrospectively by reviewing medical records. Adverse events (APE recurrence and all-cause mortality) of all enrolled patients were followed up via telephone. D-dimer > 0.50 mg/L, NT-ProBNP > 500 pg/mL, and cTnI > 0.40 ng/mL were defined as the abnormal. Kaplan-Meier curve was used to compare the cumulative survival rate between patients with different numbers of abnormal markers. Cox proportional hazard regression model was used to further test the association between numbers of abnormal markers and long-term prognosis of patients with APE after adjusting for potential confounding. During follow-up, APE recurrence and all-cause mortality happened in 78 (30.1%) patients. The proportion of APE recurrence and death in one abnormal marker, two abnormal markers, and three abnormal markers groups were 7.69%, 28.21%, and 64.10% respectively. Patients with three abnormal markers had the lowest survival rate than those with one or two abnormal markers (Log-rank test, P < 0.001). After adjustment, patients with two or three abnormal markers had a significantly higher risk of the total adverse event compared to those with one abnormal marker. The hazard ratios (95% confidence interval) were 6.27 (3.24, 12.12) and 10.7 (4.1, 28.0), respectively. Separate analyses for APE recurrence and all-cause death found similar results. A joint test of abnormal D-dimer, NT-ProBNP, and cTnI in APE patients could better predict the long-term risk of APE recurrence and all-cause mortality.

Identifiants

pubmed: 34290322
doi: 10.1038/s41598-021-94346-7
pii: 10.1038/s41598-021-94346-7
pmc: PMC8295248
doi:

Substances chimiques

Biomarkers 0
Fibrin Fibrinogen Degradation Products 0
Peptide Fragments 0
Troponin I 0
fibrin fragment D 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

14909

Informations de copyright

© 2021. The Author(s).

Références

Clin Res Cardiol. 2013 Jan;102(1):73-80
pubmed: 23011575
Circulation. 2003 May 27;107(20):2545-7
pubmed: 12742987
J Am Coll Cardiol. 2010 May 11;55(19):2150-7
pubmed: 20447541
Am J Med. 2018 Dec;131(12):1438-1443
pubmed: 30125536
Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Mar;44(3):197-211
pubmed: 26988674
Blood Coagul Fibrinolysis. 2017 Dec;28(8):675-680
pubmed: 28957940
Eur Heart J. 2008 Sep;29(18):2276-315
pubmed: 18757870
Clin Appl Thromb Hemost. 2015 Apr;21(3):273-84
pubmed: 24023267
Lung. 2015 Oct;193(5):639-51
pubmed: 26134045
Br J Haematol. 2018 Mar;180(5):694-704
pubmed: 29359796
N Engl J Med. 1992 May 7;326(19):1240-5
pubmed: 1560799
Thromb Res. 2013 Jun;131(6):e235-9
pubmed: 23562569
Crit Care Med. 2007 Aug;35(8):1937-41
pubmed: 17581488
Med Clin (Barc). 2015 Mar 15;144(6):241-6
pubmed: 24947203
Blood. 2014 Jul 10;124(2):196-203
pubmed: 24879813
J Emerg Med. 2017 Feb;52(2):137-150
pubmed: 27751702
Radiology. 2005 Jun;235(3):798-803
pubmed: 15845793
Chest. 2015 Mar;147(3):685-694
pubmed: 25079900
Circulation. 2011 Apr 26;123(16):1788-830
pubmed: 21422387
Eur Heart J. 2015 Oct 14;36(39):2642
pubmed: 26224077
Am Heart J. 2008 Aug;156(2):308-14
pubmed: 18657661
Circulation. 2003 Apr 1;107(12):1576-8
pubmed: 12668488
Eur Heart J. 2005 Oct;26(20):2166-72
pubmed: 15911566
J Cardiol. 2015 Dec;66(6):460-5
pubmed: 25843673

Auteurs

Xiaoyu Liu (X)

Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 57 East Xinhua Rd, Tangshan, Hebei, China.

Liying Zheng (L)

Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 57 East Xinhua Rd, Tangshan, Hebei, China.

Jing Han (J)

Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 57 East Xinhua Rd, Tangshan, Hebei, China.

Lu Song (L)

Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 57 East Xinhua Rd, Tangshan, Hebei, China.

Hemei Geng (H)

Hospital Infection Management Division, Kailuan General Hospital, 57 East Xinhua Rd, Tangshan, Hebei, China. 908860297@qq.com.

Yunqiu Liu (Y)

Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 57 East Xinhua Rd, Tangshan, Hebei, China. tshxnk@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH